Skip to main content
NCBI home page
British Journal of Clinical Pharmacology logoLink to British Journal of Clinical Pharmacology
. 1990 Jun;29(6):770–773. doi: 10.1111/j.1365-2125.1990.tb03701.x

Lack of effect of the specific cholecystokinin receptor antagonist loxiglumide on cholecystokinin clearance from plasma in man.

M C Jebbink 1, J B Jansen 1, A A Masclee 1, C B Lamers 1
PMCID: PMC1380182  PMID: 2378793

Abstract

Saline or loxiglumide (2.5 mg kg-1 in 10 min, followed by 5 mg kg-1 h-1 for 200 min) was administered intravenously in random order to six healthy subjects. After 60 min cholecystokinin (CCK-33) was infused (0.5 i.d.u. kg-1 h-1 for 1 h then 1.0 i.d.u. kg-1 h-1 for 1 h). Loxiglumide did not change basal levels of CCK and did not augment plasma CCK-immunoreactivity during CCK-33 infusion. After cessation of the CCK-infusion, plasma CCK concentrations decreased rapidly to basal values within 12 min, and the elimination half-life during loxiglumide infusion (4.8 +/- 0.8 min) was not significantly different from that during saline infusion (4.2 +/- 1.0 min). These results suggest that loxiglumide does not interfere with the distribution and metabolism of CCK.

Full text

PDF
770

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Adler G., Müllenhoff A., Koop I., Bozkurt T., Göke B., Beglinger C., Arnold R. Stimulation of pancreatic secretion in man by a protease inhibitor (camostate). Eur J Clin Invest. 1988 Feb;18(1):98–104. doi: 10.1111/j.1365-2362.1988.tb01173.x. [DOI] [PubMed] [Google Scholar]
  2. Douglas B. R., Jebbink M. C., Tjon a Tham R. T., Jansen J. B., Lamers C. B. The effect of loxiglumide (CR-1505) on basal and bombesin-stimulated gallbladder volume in man. Eur J Pharmacol. 1989 Jul 18;166(2):307–309. doi: 10.1016/0014-2999(89)90073-3. [DOI] [PubMed] [Google Scholar]
  3. Gomez G., Upp J. R., Jr, Lluis F., Alexander R. W., Poston G. J., Greeley G. H., Jr, Thompson J. C. Regulation of the release of cholecystokinin by bile salts in dogs and humans. Gastroenterology. 1988 Apr;94(4):1036–1046. doi: 10.1016/0016-5085(88)90564-1. [DOI] [PubMed] [Google Scholar]
  4. Hosotani R., Chowdhury P., McKay D., Rayford P. L. L364718, a new CCK antagonist, inhibits biological actions of CCK in conscious dogs. Peptides. 1987 Nov-Dec;8(6):1061–1064. doi: 10.1016/0196-9781(87)90137-9. [DOI] [PubMed] [Google Scholar]
  5. Jansen J. B., Jebbink M. C., Mulders H. J., Lamers C. B. Effect of pancreatic enzyme supplementation on postprandial plasma cholecystokinin secretion in patients with pancreatic insufficiency. Regul Pept. 1989 Jun-Jul;25(3):333–342. doi: 10.1016/0167-0115(89)90181-x. [DOI] [PubMed] [Google Scholar]
  6. Jansen J. B., Lamers C. B. Molecular forms of cholecystokinin in human plasma during infusion of bombesin. Life Sci. 1983 Nov 28;33(22):2197–2205. doi: 10.1016/0024-3205(83)90291-6. [DOI] [PubMed] [Google Scholar]
  7. Jansen J. B., Lamers C. B. Molecular forms of cholecystokinin in plasma from normal and gastrectomized human subjects following a fat meal. Peptides. 1987 Sep-Oct;8(5):801–805. doi: 10.1016/0196-9781(87)90062-3. [DOI] [PubMed] [Google Scholar]
  8. Jansen J. B., Lamers C. B. Radioimmunoassay of cholecystokinin in human tissue and plasma. Clin Chim Acta. 1983 Jul 15;131(3):305–316. doi: 10.1016/0009-8981(83)90100-6. [DOI] [PubMed] [Google Scholar]
  9. Jansen J. B., Lamers C. B. Radioimmunoassay of cholecystokinin: production and evaluation of antibodies. J Clin Chem Clin Biochem. 1983 Jun;21(6):387–394. doi: 10.1515/cclm.1983.21.6.387. [DOI] [PubMed] [Google Scholar]
  10. Koop I., Fellgiebel A., Koop H., Schafmayer A., Arnold R. Effect of cholestyramine on plasma cholecystokinin and pancreatic polypeptide levels, and exocrine pancreatic secretion. Eur J Clin Invest. 1988 Oct;18(5):517–523. doi: 10.1111/j.1365-2362.1988.tb01050.x. [DOI] [PubMed] [Google Scholar]
  11. Koop I., Koop H., Gerhardt C., Schafmayer A., Arnold R. Do bile acids exert a negative feedback control of cholecystokinin release? Scand J Gastroenterol. 1989 Apr;24(3):315–320. doi: 10.3109/00365528909093053. [DOI] [PubMed] [Google Scholar]
  12. Meyer B. M., Werth B. A., Beglinger C., Hildebrand P., Jansen J. B., Zach D., Rovati L. C., Stalder G. A. Role of cholecystokinin in regulation of gastrointestinal motor functions. Lancet. 1989 Jul 1;2(8653):12–15. doi: 10.1016/s0140-6736(89)90255-9. [DOI] [PubMed] [Google Scholar]
  13. Sakamoto T., Fujimura M., Newman J., Zhu X. G., Greeley G. H., Jr, Thompson J. C. Comparison of hepatic elimination of different forms of cholecystokinin in dogs. Bioassay and radioimmunoassay comparisons of cholecystokinin-8-sulfate and -33-sulfate. J Clin Invest. 1985 Jan;75(1):280–285. doi: 10.1172/JCI111686. [DOI] [PMC free article] [PubMed] [Google Scholar]
  14. Setnikar I., Chisté R., Makovec F., Rovati L. C., Warrington S. J. Pharmacokinetics of loxiglumide after single intravenous or oral doses in man. Arzneimittelforschung. 1988 May;38(5):716–720. [PubMed] [Google Scholar]
  15. Strunz U. T., Walsh J. H., Grossman M. I. Removal of gastrin by various organs in dogs. Gastroenterology. 1978 Jan;74(1):32–33. [PubMed] [Google Scholar]
  16. Thompson J. C., Fender H. R., Ramus N. I., Villar H. V., Rayford P. L. Cholecystokinin metabolism in man and dogs. Ann Surg. 1975 Oct;182(4):496–504. doi: 10.1097/00000658-197510000-00015. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. Walsh J. H., Debas H. T., Grossman M. I. Pure human big gastrin. Immunochemical properties, disappearance half time, and acid-stimulating action in dogs. J Clin Invest. 1974 Aug;54(2):477–485. doi: 10.1172/JCI107783. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Clinical Pharmacology are provided here courtesy of British Pharmacological Society

RESOURCES